Rhodia SA's Aspirin and Salicylic Unit

Rhodia SA's Aspirin and Salicylic Unit is a specialized manufacturer focusing on the production of aspirin and salicylic acid, catering to a diverse range of industries including pharmaceuticals and healthcare. Rhodia SA's Aspirin and Salicylic Unit manufactures key pharmaceutical ingredients, specifically aspirin and salicylic acid. The unit was acquired by Novacap, a portfolio company of AXA Private Equity, in November 2011. The company's headquarters is located in Paris, France.

The company specializes in producing aspirin and salicylic acid, essential ingredients used across various sectors, particularly in pharmaceuticals. These products are crucial in manufacturing pain relief medications and other therapeutic applications, serving a wide client base that includes pharmaceutical companies globally. The unit's offerings are marketed primarily in North America, Europe, and parts of Asia, meeting the demands for high-quality chemical compounds in the healthcare sector. In the most recent year reported, Rhodia SA's Aspirin and Salicylic Unit generated a revenue of USD 132.

70 mn for the year 2011. Following its acquisition in November 2011, Rhodia SA's Aspirin and Salicylic Unit is expected to leverage Novacap's resources to enhance its product line and expand its market presence. The focus will be on developing new formulations and exploring entry into emerging markets in Asia and Latin America over the next few years. The recent acquisition will provide the necessary capital to support these growth initiatives.